Accepting a confirmed diagnosis of canine Addison’s disease may not be easy, but for many dog owners the diagnosis can be a blessing in disguise. Once your client knows what their dog is facing, it can help them regain control and take
the appropriate action.
As the first FDA-approved treatment for canine Addison's disease*, Percorten-V has a long history of proven success. With careful monitoring and regular injections, Percorten-V can help your patients lead a normal life.2,4,5
Talk to your Elanco representative today about the solution that's saved nearly 70,000 dogs1
Percorten-V is an injectable suspension of desoxycorticosterone pivalate (DOCP).
- DOCP replaces the mineralocorticoid hormones not produced by Addisonian dogs
- Administered via easy, intramuscular doses every 21 to 30 days**
- Animals suffering from hypovolemia, pre-renal azotemia, and inadequate tissue perfusion must be rehydrated with intravenous fluid (saline) therapy, and primary renal disease should be ruled out before starting Percorten-V therapy.
*For use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency.
**The initial starting dose of Percorten-V is 1 mg/lb intramuscular injection every 25 days. For most dogs, a dose range of 0.75 mg/lb to 1.0 mg/lb (1.65 mg/kg to 2.2 mg/kg) given every 21 to 30 days is effective. Glucocorticoid
replacement must be supplied by small daily doses of glucocorticoid hormones (e.g., prednisone or prednisolone at 0.2 to 0.4 mg/kg). Dosage requirements are variable and must be individualized on the basis of the response of the patient to therapy.
Important Safety Information
Do not use in pregnant dogs or in dogs suffering from congestive heart failure, severe renal disease, or edema. Reduce dosage in dogs showing signs of hypernatremia or hypokalemia.
Like other adrenocortical hormones, Percorten-V may cause severe side effects if dosage is too high or prolonged.
The most common adverse reactions reported were depression/lethargy, vomiting, anorexia, polydipsia, and polyuria. Some of these effects may resolve with adjustments in dose or interval of Percorten-V or concomitant glucocorticoid administration. Please click here
for full product information.
The following case studies provide examples of the variable clinical signs of canine hyperadrenocorticism and the value of early diagnosis and prompt initiation of treatment with Percorten-V.
For more information, talk to your Elanco representative today.